Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. (9th December 2020)

• Record Type: Journal Article
• Authors: Di, Mengyang; Huntington, Scott F; Olszewski, Adam J.
• Is Part Of: Oncologist. Volume 26:Number 2(2021)
• Page Start: 120
• Page End: 132
• Publication Date: 2020-12-09
• Subjects: Lymphoma -- Large B‐cell -- Diffuse -- Geriatric assessment polatuzumab vedotin -- Tafasitamab -- CAR T‐cell -- Antibodies -- Bispecific; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1002/onco.13610
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: : Most patients with diffuse large B‐cell lymphoma (DLBCL) are diagnosed at age 60 years or older. Challenges to effective therapy among older individuals include unfavorable biologic features of DLBCL, geriatric vulnerabilities, suboptimal treatment selection, and toxicities of cytotoxic chemotherapy. Wider application of geriatric assessments may help identify fit older patients who benefit from standard immunochemotherapy without unnecessary dose reductions. Conversely, attenuated regimens may provide a better balance of risk and benefit for selected unfit or frail patients. Supportive care with the use of corticosteroid‐based prephase, prophylactic growth factors, and early institution of supportive and palliative care can help maximize treatment tolerance. Several novel or emerging therapies have demonstrated favorable toxicity profiles, thus facilitating effective treatment for elderly patients. In the relapsed or refractory setting, patients who are not candidates for stem cell transplantation can benefit from newly approved options including polatuzumab vedotin‐based combinations or tafasitamab plus lenalidomide, which may have higher efficacy and/or lower toxicity than historical chemotherapy regimens. Chimeric antigen receptor T‐cell therapy has been successfully applied to older patients outside of clinical trials. In the first‐line setting, emerging immunotherapy options (bispecific antibodies) and targeted therapies (anti‐CD20 antibodies combined with lenalidomide and/or B‐cell receptor inhibitors) may provide chemotherapy‐free approaches for DLBCL. Enrolling older patients in clinical trials will be paramount to fully examine potential efficacy and toxicity of these strategies. In this review, we discuss recent advances in fitness stratification and therapy that have expanded curative options for older patients, as well as future opportunities to improve outcomes in this population. Implications for Practice: Management of diffuse large B‐cell lymphoma in older patients poses challenges due to aggressive disease biology and geriatric vulnerability. Although R‐CHOP remains standard first‐line treatment, geriatric assessment may help evaluate patients' fitness for immunochemotherapy. Corticosteroid prephase, prophylactic growth factors, and early palliative care can improve tolerance of treatment. Novel salvage options (polatuzumab vedotin‐based combinations, tafasitamab plus lenalidomide) or chimeric antigen receptor T‐cell therapy should be considered in the relapsed or refractory setting for patients ineligible for stem cell transplantation. Emerging immunotherapies (bispecific antibodies) and targeted therapies provide potential first‐line chemotherapy‐free approaches, which need to be rigorously assessed in clinical trials that involve geriatric patients. Abstract : Diffuse large B‐cell lymphoma (DLBCL) is an aggressive but potentially curable cancer that mainly affects older individuals. This review presents recent advances in fitness stratification and therapy that have expanded curative options for older patients with DLBCL and future opportunities to improve outcomes in this population.